Latest Share Chat

REMOVE ADS

Astrazeneca Regulatory News (AZN)

Astrazeneca Information

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes

Get Live Data

13,858.00 304.00 (2.24%)

Bid:

13,842.00

Ask:

13,846.00

Spread: 4.00 (0.029%)

Market Cap: £214.92b

Last checked at -

Intraday Astrazeneca Share Chart

REMOVE ADS

EMTN Programme Routine Technical Update

11 Jun 2020 07:00

RNS Number : 6000P

AstraZeneca PLC

11 June 2020

11 June 2020 07:00 BST

EMTN Programme Routine Technical Update: Publication of Prospectus

Following a routine technical update of the Company's Euro Medium Term Note ("EMTN") programme established in 2007, the following prospectus has been approved by the Financial Conduct Authority and is available for viewing:

Base Prospectus for the AstraZeneca PLC U.S. $10,000,000,000 Euro Medium Term Note Programme (the "Prospectus").

The last drawdown under the EMTN programme was in 2016.

To view the full document, please paste the following URL into the address bar of your browser.

http://www.rns-pdf.londonstockexchange.com/rns/6000P_1-2020-6-10.pdf

A copy of the above Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at:

http://www.morningstar.co.uk/uk/NSM

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

PDIFLFFARAIILII

Date		Source	Headline
16th Oct 2018	7:00 am	RNS	FDA Orphan Drug for Lynparza in pancreatic cancer
1st Oct 2018	3:00 pm	RNS	Total Voting Rights
1st Oct 2018	7:00 am	RNS	Atacand Agreement with Cheplapharm Completed
28th Sep 2018	4:00 pm	RNS	Previous Announcement Regarding Appointment Of NED
25th Sep 2018	1:15 pm	RNS	Overall survival data for Imfinzi: Stage III NSCLC
24th Sep 2018	4:10 pm	RNS	EMA approves AZ's Imfinzi for Stage III NSCLC
24th Sep 2018	7:00 am	RNS	Farxiga gets positive result in DECLARE-TIMI 58
14th Sep 2018	7:00 am	RNS	FDA approves AZ's Lumoxiti in hairy cell leukaemia
7th Sep 2018	7:00 am	RNS	Tezepelumab FDA Breakthrough Therapy Designation
6th Sep 2018	7:00 am	RNS	Directorate Change
3rd Sep 2018	3:00 pm	RNS	Total Voting Rights
31st Aug 2018	7:00 am	RNS	AstraZeneca Update on Anifrolumab in SLE
30th Aug 2018	7:00 am	RNS	EC approves Bydureon BCise device for T2 diabetes
23rd Aug 2018	7:00 am	RNS	AstraZeneca PIIIb trial update for Bevespi in COPD
21st Aug 2018	7:00 am	RNS	AZ's Tagrisso approved in Japan for 1st-line NSCLC
15th Aug 2018	7:00 am	RNS	AstraZeneca prices a $3bn bond issue
3rd Aug 2018	7:00 am	RNS	EMA grants OD for selumetinib in NF1
1st Aug 2018	3:00 pm	RNS	Total Voting Rights
27th Jul 2018	2:00 pm	RNS	CHMP recommends Imfinzi for Stage III nsclc
26th Jul 2018	7:00 am	RNS	AZN: H1 2018 Results
24th Jul 2018	7:00 am	RNS	Atacand to be divested to Cheplapharm in Europe
18th Jul 2018	4:11 pm	RNS	Holding(s) in Company
18th Jul 2018	12:00 pm	RNS	Holding(s) in Company
2nd Jul 2018	3:00 pm	RNS	Total Voting Rights
2nd Jul 2018	7:00 am	RNS	Lynparza approved in Japan for BRCAm breast cancer
2nd Jul 2018	7:00 am	RNS	Imfinzi approved in Japan for Stage III nsclc
29th Jun 2018	3:00 pm	RNS	Bydureon receives positive CHMP opinion for BCise
28th Jun 2018	1:30 pm	RNS	AZ and Luye Pharma complete agreement for Seroquel
27th Jun 2018	7:00 am	RNS	Lynparza: significant PFS 1st-line ovarian cancer
26th Jun 2018	7:00 am	RNS	Board Committee Changes
22nd Jun 2018	7:00 am	RNS	Publication of a Prospectus
12th Jun 2018	7:00 am	RNS	Update: lanabecestat Phase III Alzheimer's trials
8th Jun 2018	5:30 pm	RNS	EU APPROVES TAGRISSO FOR 1ST-LINE NSCLC
8th Jun 2018	7:00 am	RNS	Director Declaration
1st Jun 2018	3:00 pm	RNS	Block listing Interim Review
1st Jun 2018	3:00 pm	RNS	Total Voting Rights
1st Jun 2018	11:00 am	RNS	Director Declaration
30th May 2018	7:00 am	RNS	Update on TERRANOVA PIII trial for Fasenra in COPD
25th May 2018	7:00 am	RNS	AZ's Imfinzi: significant OS in Stage III nsclc
21st May 2018	7:00 am	RNS	AZ regulatory submission in Japan for Forxiga
21st May 2018	7:00 am	RNS	US FDA approves Lokelma for adult hyperkalaemia
18th May 2018	5:30 pm	RNS	Result of AGM
18th May 2018	7:00 am	RNS	AZN: Q1 2018 Results
11th May 2018	7:00 am	RNS	AstraZeneca update on Fasenra PIII trial in COPD
8th May 2018	11:00 am	RNS	EMA approves Lynparza: maintenance ovarian cancer
8th May 2018	7:00 am	RNS	AZ and Luye Pharma enter agreement for Seroquel
4th May 2018	12:00 pm	RNS	Director Declaration
1st May 2018	3:00 pm	RNS	Total Voting Rights
27th Apr 2018	12:30 pm	RNS	AZ: positive CHMP for Tagrisso first-line nsclc
24th Apr 2018	7:00 am	RNS	AstraZeneca:high level results of the ARCTIC trial

Latest Share Chat

Astrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

Intraday Astrazeneca Share Chart

EMTN Programme Routine Technical Update

Please enter at least 2 characters

No results found

Search results

Recently viewed

Trending